Inventor · disambiguated record
Christoph Rader
Also filed as: RADER CHRISTOPH
26 granted patents·18 pending applications·2,019 citations·filing 1999–2025
97Inventor score
Top patents by PatentIndex Score
44 records- 0199US7087409B2Humanization of murine antibodySCRIPPS RESEARCH INST·Filed 2002·Granted Aug 8, 2006·1.4k cites·12 claims
- 0296US11242388B2ROR1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2020·Granted Feb 8, 2022·8 cites·12 claims
- 0396US9163258B2Method for the treatment of obesityRIDDELL STANLEY R·Filed 2011·Granted Oct 20, 2015·41 cites·13 claims
- 0495US6677435B2Prodrug activation using catalytic antibodiesSCRIPPS RESEARCH INST·Filed 2001·Granted Jan 13, 2004·103 cites·5 claims
- 0594US9316646B2Anti-human ROR1 antibodiesRADER CHRISTOPH·Filed 2010·Granted Apr 19, 2016·45 cites·32 claims
- 0693US10618959B2ROR1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2018·Granted Apr 14, 2020·11 cites·26 claims
- 0792US9273136B2Fully human anti-human NKG2D monoclonal antibodiesRADER CHRISTOPH·Filed 2009·Granted Mar 1, 2016·67 cites·16 claims
- 0892US6268488B1Prodrug activation using catalytic antibodiesFiled 1999·Granted Jul 31, 2001·139 cites·15 claims
- 0991US9758586B2Chimeric rabbit/human ROR1 antibodiesRADER CHRISTOPH·Filed 2011·Granted Sep 12, 2017·25 cites·23 claims
- 1090US8252902B2Antibody targeting compoundsBARBAS CARLOS F·Filed 2002·Granted Aug 28, 2012·32 cites·28 claims
- 1189US6342587B1A33 antigen specific immunoglobulin products and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Jan 29, 2002·93 cites·15 claims
- 1288US10851149B2Treatment of cancer using GFR α-4 chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2015·Granted Dec 1, 2020·3 cites·32 claims
- 1388US8916159B2Selenocysteine mediated hybrid antibody moleculesRADER CHRISTOPH·Filed 2009·Granted Dec 23, 2014·13 cites·22 claims
- 1487US8877199B2B cell surface reactive antibodiesRADER CHRISTOPH·Filed 2010·Granted Nov 4, 2014·16 cites·17 claims
- 1587US6346249B1Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin productsLUDWIG INST CANCER RES·Filed 2000·Granted Feb 12, 2002·13 cites·19 claims
- 1685US11078273B2ROR2 antibody compositions and related methodsSCRIPPS RESEARCH INST·Filed 2017·Granted Aug 3, 2021·2 cites·13 claims
- 1783US10011635B2Cyclic peptide conjugates and methods of useH LEE MOFFITT CANCER CT & RES·Filed 2014·Granted Jul 3, 2018·3 cites·9 claims
- 1880US10035848B2Antibody targeting cell surface deposited complement protein C3d and use thereofUS HEALTH·Filed 2015·Granted Jul 31, 2018·4 cites·25 claims
- 1980US2024262884A1Treatment of cancer using gfr alpha-4 chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2024·Application pending·0 cites
- 2079US12281167B2Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)UNIV PENNSYLVANIA·Filed 2023·Granted Apr 22, 2025·0 cites·17 claims
- 2179US11078235B2Cyclic peptide conjugates and methods of useH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Aug 3, 2021·1 cites·3 claims
- 2273US2025296989A1ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOFUS HEALTH·Filed 2024·Application pending·0 cites
- 2370US2022153839A1Ror1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 2469US11834501B2ROR2 antibody compositions and related methodsUNIV FLORIDA·Filed 2021·Granted Dec 5, 2023·0 cites·10 claims
- 2569US2025230249A1Humanized anti-gdnf family alpha-receptor 4 (grf-alpha-4) antibodies and chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2025·Application pending·0 cites
- 2668US11970525B2Treatment of cancer using GFR alpha-4 chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2020·Granted Apr 30, 2024·0 cites·20 claims
- 2767US11802159B2Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)UNIV PENNSYLVANIA·Filed 2020·Granted Oct 31, 2023·0 cites·29 claims
- 2864US2025011422A1Siglec-6 antibodies, derivative compounds and related usesUNIV FLORIDA·Filed 2022·Application pending·0 cites
- 2958US2025312472A1Antibody compounds with reactive cysteine and related antibody drug conjugatesUNIV FLORIDA·Filed 2023·Application pending·0 cites
- 3056US12286487B2Antibody compounds with reactive arginine and related antibody drug conjugatesUNIV FLORIDA·Filed 2019·Granted Apr 29, 2025·0 cites·34 claims
- 3155US11384139B2Antibody targeting cell surface deposited complement protein C3d and use thereofUS HEALTH·Filed 2018·Granted Jul 12, 2022·0 cites·20 claims
- 3254US2013171074A1Targeting compoundsSCRIPPS RESEARCH INST·Filed 2013·Application pending·0 cites
- 3353US2015104383A1Selenocysteine mediated hybrid antibody moleculesUS HEALTH·Filed 2014·Application pending·0 cites
- 3452US2015086575A1B cell surface reactive antibodiesUS HEALTH·Filed 2014·Application pending·0 cites
- 3552US2023029635A1ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOFUS HEALTH·Filed 2020·Application pending·0 cites
- 3651US2016095883A1Method for the treatment of obesityDEPT OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY·Filed 2015·Application pending·0 cites
- 3750US2003190676A1Antibody targeting compoundsSCRIPPS RESEARCH INST·Filed 2003·Application pending·0 cites
- 3849US2018100020A1Chimeric rabbit/human ror1 antibodiesUS HEALTH·Filed 2017·Application pending·0 cites
- 3949US2023143003A1Affinity matured and humanized binding domains targeting ror2UNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 4047US2023140868A1Compositions and methods for treating cancerALPHA BETA HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 4146US2023012213A1Novel conjugation chemistry for catalytic antibody 38c2UNIV FLORIDA·Filed 2020·Application pending·0 cites
- 4243US11197934B2Dual variable domain immunoconjugates and uses thereofSCRIPPS RESEARCH INST·Filed 2016·Granted Dec 14, 2021·0 cites·21 claims
- 4341US2003129188A1Integrin targeting compoundsSCRIPPS RESEARCH INST·Filed 2002·Application pending·0 cites
- 4426US2012201811A1Generation and use of fab, scfv, and related binding molecules specific for hiv-1 revSTAHL STEPHEN J·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christoph Rader files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →